Lipids have a variety of important biological functions; abnormal lipid metabolism is an important factor in the occurrence and development of atherosclerosis. The lipid and atherosclerosis research center aims to combine biological mass spectrometry and other technologies, targeting physiological and pathological conditions (atherosclerosis, stroke, metabolic syndrome), and various lipids including phospholipids, sphingolipids, glycerides and related lipid molecules that are metabolized by intestinal microflora are analyzed to study lipid differences in complex samples such as plasma, tissues or other biological fluids, and to clarify lipid metabolism and lipid function in different disease states. In combination with genetically engineered animal models, we study the molecular mechanisms through biological functions of differential lipids.
In clinical research, we established a large sample database of atherosclerotic cerebrovascular disease to carry out epidemiological, genetic and epigenetic studies, and focused on the exploration of lipid metabolism testing items and lipid-adjusting drug data in the database. At the same time, new lipid markers were screened from clinical samples of different diseases to realize early diagnosis and treatment of diseases. The center aims to build a research platform, integrating the clinicians and researchers in the field of lipid, and to use cutting-edge biological technologies, including mass spectrometry, flow cytometry, bioimaging technology, and basic vascular function research, to complete a new clinical diagnosis, disease classification/mechanism and drug target development, and jointly promote the development of cardiovascular and cerebrovascular (including cerebrovascular and peripheral vascular) diagnosis and treatment.
Main responsibilities of the department: To study lipid differences in complex samples such as plasma, tissues or other biological fluids, clarify lipid metabolism and lipid function in different disease states; to establish a large sample database of atherosclerotic cerebrovascular diseases in clinical research, with emphasis on mining data in the database and screening new lipid markers; to construct a lipid platform and integrate clinical researchers. Using frontier biotechnology (mass spectrometry, flow cytometry, bioimaging) and basic vascular functional research, we have completed clinical diagnosis, disease typing/mechanism and drug target development.
Lemin Zheng, Director of Lipid Metabolism and Atherosclerosis Center
Professor, National Youth Plan “Youth Top Talent”